Centauri Therapeutics closes £24 million GBP Series A investment round
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates
23-Feb-2022 -
Centauri Therapeutics Limited, an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announced the close of its £24 million GBP (c. 32 million USD) Series A investment round. The funds will support the continued advancement of the ...
antimicrobial resistance
immunotherapies
infectious diseases
+1